person · Reporting owner
Fenimore Christopher R.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Finance CFO | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,984 |
Ending reported balance
After 2026-08-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-18 · Exercise / conversion · Acquired 6,283 · Balance 24,583 Row 2 · 2026-08-18 · Tax withholding · Disposed 4,599 · Balance 19,984 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $381.92 · Expires 2026-12-16 | Direct | 6,000 |
Reported balance
After 2026-08-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-18 · Exercise / conversion · Disposed 6,283 · Balance 6,000 F2: The stock option award vested in four equal annual installments, commencing one year after the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 1,574 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,574 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 1,897 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,897 F1: These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust. |
| Common StockSEC Table I · non-derivative | Indirectby Trust for Daugh | 25 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 25 |
| Common StockSEC Table I · non-derivative | Indirectby Trust for Son | 25 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 25 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.
F2: The stock option award vested in four equal annual installments, commencing one year after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 23, 2023 Filed Aug 25, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 7,000 | $399.66 | $2,797,620.00 |
DisclosureSEC source: 0001968202-23-000031 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 20:37 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,192 | $806.47 | $1,767,782.24 |
DisclosureSEC source: 0001883850-23-000060 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,409 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 9, 2023. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $270.43 | $0.00 |
DisclosureSEC source: 0001883850-23-000037 · edgardoc.xml · derivative · entry 9 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2023-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 3,286 | $774.29 | $2,544,316.94 |
DisclosureSEC source: 0001883850-23-000037 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,295 Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,000 | $270.43 | $1,352,150.00 |
DisclosureSEC source: 0001883850-23-000037 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,111 | $0.00 Strike: $726.53 | $0.00 |
DisclosureSEC source: 0001883850-22-000131 · edgardoc.xml · derivative · entry 8 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,111 Underlying: Common Stock · 7,111 shares Expires 2032-12-16 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 1,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000131 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,581 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 16, 2024 and 50% on December 16, 2026. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 247 | $753.28 | $186,060.16 |
DisclosureSEC source: 0001883850-22-000117 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,655 Read SEC document |
| October 26, 2022 Filed Dec 13, 2022 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 435 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000117 · edgardoc.xml · nonDerivative · entry 4 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 460 Read SEC document |
| October 26, 2022 Filed Dec 13, 2022 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 436 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000117 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Daugh Disclosed balance after: 461 Read SEC document |
| October 26, 2022 Filed Dec 13, 2022 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 871 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000117 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Indirect · by 2018 GRAT Disclosed balance after: 0 Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,844 | $749.00 | $1,381,156.00 |
DisclosureSEC source: 0001883850-22-000080 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,425 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,346 | $724.00 | $2,422,504.00 |
DisclosureSEC source: 0001883850-22-000077 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,269 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 20:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,450 | $0.00 Strike: $555.67 | $0.00 |
DisclosureSEC source: 0001708138-22-000039 · edgardoc.xml · derivative · entry 12 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 2,450 shares Expires 2025-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 20:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $270.43 | $0.00 |
DisclosureSEC source: 0001708138-22-000039 · edgardoc.xml · derivative · entry 11 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2023-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 20:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 3,451 | $736.21 | $2,540,660.71 |
DisclosureSEC source: 0001708138-22-000039 · edgardoc.xml · nonDerivative · entry 4 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,615 Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 20:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,000 | $270.43 | $1,352,150.00 |
DisclosureSEC source: 0001708138-22-000039 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 20:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,155 | $736.21 | $1,586,532.55 |
DisclosureSEC source: 0001708138-22-000039 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,066 Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 20:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,450 | $555.67 | $1,361,391.50 |
DisclosureSEC source: 0001708138-22-000039 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $555.67 | $0.00 |
DisclosureSEC source: 0001883850-22-000029 · edgardoc.xml · derivative · entry 12 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,450 Underlying: Common Stock · 2,000 shares Expires 2025-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $270.43 | $0.00 |
DisclosureSEC source: 0001883850-22-000029 · edgardoc.xml · derivative · entry 11 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2023-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 6,857 | $700.99 | $4,806,688.43 |
DisclosureSEC source: 0001883850-22-000029 · edgardoc.xml · nonDerivative · entry 4 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,771 Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 10,000 | $270.43 | $2,704,300.00 |
DisclosureSEC source: 0001883850-22-000029 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,797 | $700.99 | $1,259,679.03 |
DisclosureSEC source: 0001883850-22-000029 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,628 Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,000 | $555.67 | $1,111,340.00 |
DisclosureSEC source: 0001883850-22-000029 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2021 Filed Dec 14, 2021 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 270 | $664.34 | $179,371.80 |
DisclosureSEC source: 0001708138-21-000106 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,122 Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:28 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,941 | $0.00 Strike: $644.54 | $0.00 |
DisclosureSEC source: 0001883850-21-000022 · edgardoc.xml · derivative · entry 8 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,941 Underlying: Common Stock · 7,941 shares Expires 2031-12-08 F3 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:28 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 1,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-21-000022 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,392 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2023 and 50% on December 8, 2025. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 14 | $665.21 | $9,312.94 |
DisclosureSEC source: 0001237899-21-000017 · edgardoc.xml · nonDerivative · entry 8 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,739 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 70 | $663.05 | $46,413.50 |
DisclosureSEC source: 0001237899-21-000017 · edgardoc.xml · nonDerivative · entry 7 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,753 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 70 shares of Company stock on August 23, 2021 at prices ranging from $663.00 to $663.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $662.78 | $662.78 |
DisclosureSEC source: 0001237899-21-000017 · edgardoc.xml · nonDerivative · entry 6 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,823 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 88 | $661.89 | $58,246.32 |
DisclosureSEC source: 0001237899-21-000017 · edgardoc.xml · nonDerivative · entry 5 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,824 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 88 shares of Company stock on August 23, 2021 at prices ranging from $661.47 to $661.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 23 | $660.33 | $15,187.59 |
DisclosureSEC source: 0001237899-21-000017 · edgardoc.xml · nonDerivative · entry 4 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,912 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 23 shares of Company stock on August 23, 2021 at prices ranging from $660.09 to $660.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $659.33 | $5,933.97 |
DisclosureSEC source: 0001237899-21-000017 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,935 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on August 23, 2021 at prices ranging from $659.28 to $659.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,576 | $655.00 | $2,997,280.00 |
DisclosureSEC source: 0001237899-21-000017 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,944 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $179.13 | $0.00 |
DisclosureSEC source: 0001237899-21-000017 · edgardoc.xml · derivative · entry 15 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,500 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 13,500 | $179.13 | $2,418,255.00 |
DisclosureSEC source: 0001237899-21-000017 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 20, 2021 Filed Aug 25, 2021 20:06 UTC Amendment | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 8,719 | $664.85 | $5,796,827.15 |
DisclosureSEC source: 0001104659-21-109328 · tm2125915-1_4aseq1.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · SVP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,020 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · balance_after: The amount of securities shown following the reported transaction gives effect to the other transactions reported by the Reporting Person in the Original Form 4. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $492.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000113 · edgardoc.xml · derivative · entry 9 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-12-09 F4 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000113 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,102 F2 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests in its entirety on December 9, 2024. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 969 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000113 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,352 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 9, 2022 and 50% on December 9, 2024. Read SEC document |
| September 24, 2020 Filed Dec 11, 2020 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 25 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000113 · edgardoc.xml · nonDerivative · entry 5 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Son Disclosed balance after: 25 Read SEC document |
| September 24, 2020 Filed Dec 11, 2020 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 25 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000113 · edgardoc.xml · nonDerivative · entry 4 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust for Daugh Disclosed balance after: 25 Read SEC document |
| September 24, 2020 Filed Dec 11, 2020 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 50 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000113 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Indirect · by 2017 GRAT Disclosed balance after: 0 Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11 | $658.00 | $7,238.00 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · nonDerivative · entry 16 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,501 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 82 | $647.79 | $53,118.78 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · nonDerivative · entry 15 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,512 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 155 | $646.82 | $100,257.10 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · nonDerivative · entry 14 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,594 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 155 shares of Company stock on July 21, 2020 at prices ranging from $646.71 to $646.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 72 | $645.33 | $46,463.76 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · nonDerivative · entry 13 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,749 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 303 | $644.57 | $195,304.71 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · nonDerivative · entry 12 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,821 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 303 shares of Company stock on July 21, 2020 at prices ranging from $644.32 to $644.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 691 | $643.49 | $444,651.59 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · nonDerivative · entry 11 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,124 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 691 shares of Company stock on July 21, 2020 at prices ranging from $643.00 to $643.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.